The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neurotrophic Factors Challenge, 2012Effects of Recombinant CDNF Protein in Alpha-synuclein Model of Parkinson’s Disease in Pre-Clinical Models
Objective/Rationale:Neurotrophic factors have been explored as a novel treatment for Parkinson’s disease. Toxic effect of α-synucleinopathies, one of the hallmarks in PD pathophysiology, occurs in...
-
Target Validation, 2012Small Molecule Ligand for TrkB/TrkC as a Novel Therapeutic for Parkinson's Disease
Objective/Rationale:
Ample evidence suggests that the neurotrophin (NT) receptors, TrkB and TrkC, would be particularly effective therapeutic targets for Parkinson’s disease (PD). Both... -
LRRK2 in the Immune System, 2012The Four Horsemen of G2019S
Objective/Rationale:
Using stem cell-derived neurons from individuals with Parkinson’s disease, we have found that dopaminergic neurons carrying the G2019S variant of LRRK2 are abnormally... -
MJFF Research Grant, 2012Investigation of Possible Pathological Changes in Aged LRRK2 Knockout Models
Objective/Rationale:
To determine if there are any pathological changes in either the brain, kidney, lung, spleen, liver, and heart in aged LRRK2 knockout and wild type pre-clinical... -
MJFF Research Grant, 2012Role of LRRK2 in Alpha-Synuclein-Induced Neurodegeneration
Objective/Rationale:
This project seeks to develop a robust and standardized pre-clinical model relevant to late-onset Parkinson’s disease (PD) that will identify clinically viable LRRK2 kinase... -
Therapeutics Development Initiative, 2012Peripheral Administration of XPro1595 in the Pre-clinical 6-OHDA Model of Parkinson's Disease
Objective/Rationale:
Inflammation in the brain is one of the causes of Parkinson’s disease. XPro1595 is a selective inhibitor of soluble TNF that “turns off” inflammation to stop the loss of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.